Industry Experts

Max holds a PhD in Bioengineering from Stanford University and has focused his career on the discovery and development of biologics for clinical use. He first joined Denali Therapeutics, where he worked with the antibody engineering team to develop the Transport Vehicle (TV) platform technology that actively delivers antibodies, proteins, and enzymes across the blood-brain barrier, and was the engineering lead of DNL593 for GRN- frontotemporal dementia (currently in Phase I/II clinical trials). He then joined Enlaza Therapeutics to focus on developing covalent biologics for oncology, and established and led the antibody discovery team, developed discovery platforms, and advanced biotherapeutic candidates in the pipeline. In 2024, Max joined Tentarix Biotherapeutics as Director of Mammalian Display, where core technology is leveraged to create multi-specifics for autoimmunity and immuno-oncology.